Arcutis Biotherapeutics Inc (OQ:ARQT)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 3027 Townsgate Road, Suite 300
WESTLAKE VILLAGE CA 91361
Tel: N/A
Website: https://arcutis.com
IR: See website
<
Key People
Todd Franklin Watanabe
President, Chief Executive Officer, Director
Patricia A. Turney
Senior Vice President - Operations
David W. Osborne
Co-Founder, Senior Vice President, Chief Technology Officer
David Topper
Chief Financial Officer
Todd Tucker
Chief Human Resource Officer, Senior Vice President
Masaru Matsuda
Senior Vice President, General Counsel
Ayisha Jeter
Senior Vice President - Marketing and Market Access
Patrick E. Burnett
Senior Vice President and Chief Medical Officer
Kenneth A. Lock
Senior Vice President and Chief Commercial Officer
Matthew R. Moore
Senior Vice President, Chief Business Officer
   
Business Overview
Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas, in individuals 12 years of age or older. ZORYVE cream is a once-daily topical formulation of roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor. The Company's pipeline includes ARQ-255, ARQ-252, and ARQ-234. ARQ-255 is developed for alopecia areata. ARQ-252 is an alternative topical cream formulation of ivarmacitinib that the Company is developing for chronic hand eczema and vitiligo. ARQ-255 is developed for the treatment of alopecia areata.
Financial Overview
For the fiscal year ended 31 December 2023, Arcutis Biotherapeutics Inc revenues increased from $3.7M to $59.6M. Net loss decreased 16% to $262.1M. Revenues reflect Product revenue, net increase from $3.7M to $29.2M. Lower net loss reflects Research and development - Balancing val decrease of 44% to $95M (expense), Other income (expense), net increase from $5.8M to $11.8M (income).
Employees: 296 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $1,016M as of Dec 31, 2023
Annual revenue (TTM): $59.61M as of Dec 31, 2023
EBITDA (TTM): -$239.55M as of Dec 31, 2023
Net annual income (TTM): -$262.14M as of Dec 31, 2023
Free cash flow (TTM): -$247.49M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 114,945,238 as of Mar 4, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.